Gammagard Liquid Gets FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy
January 30th 2024Gammagard Liquid is now FDA-approved to treat neuromuscular disability and impairment in adults with CIDP; as a replacement treatment for primary immunodeficiency in patients aged 2 years and older; and as a maintenance treatment to improve muscle strength and disability in adults with multifocal motor neuropathy.
Adverse Event Reports Linked to Counterfeit Ozempic on the Rise
January 26th 2024Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.
Indication for Zynrelef Expanded to Include Orthopedic, Soft Tissue Procedures
January 25th 2024Zynrelef was initially approved by the FDA for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.